drugset / Trial / NCT02338531
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase II open label Biomarker Research Study off PF-03084014 in non-metastatic triple-negative breast cancer patients with residual disease (cHEmoresistant) after completion of standard neoadjuvant chemotherapy.
Timeline
- Start
- 2015-06
- Primary completion
- 2018-09
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirogacestat | Small molecule | 150 mg | Oral |